Currently, advanced non-oncogene addicted NSCLC patients are treated in first line either with the combination of anti-PD-1/PD-L1 mAbs and chemotherapy or with anti-PD-1/PD-L1 mAbs alone, based on PD-L1 tumor expression < 50% or ≥ 50% [26, 27]. Here, PDCD1 is linked to neoplasm.